Genetic testing could improve cancer outcomes for patients, but historical research abuses and access issues have slowed ...

The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

The firm recorded $58 million in sales for the autologous TIL therapy, which it is working on moving into earlier melanoma settings and other tumor types.

The firm will use the funds to take a CD19-based in vivo CAR T therapy through IND-enabling and clinical studies for B-cell malignancies and autoimmune diseases.

The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...

Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Under the agreement, Singapore-headquartered ImmunoScape will develop what it calls a "Seed-and-Boost" immunotherapy, combining its T-cell receptor therapies (the "seed") followed by Cue's IL-2-based ...